Onconetix (NASDAQ:ONCO) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Onconetix (NASDAQ:ONCO) to a hold rating in a report published on Saturday.

Onconetix Stock Performance

NASDAQ ONCO opened at $4.26 on Friday. The company has a fifty day moving average of $6.08 and a two-hundred day moving average of $24.57. Onconetix has a 1 year low of $4.11 and a 1 year high of $1,190.00.

Onconetix (NASDAQ:ONCO) last posted its earnings results on Thursday, June 12th. The company reported $21.25 earnings per share for the quarter. The firm had revenue of $0.10 million during the quarter.

Institutional Investors Weigh In On Onconetix

An institutional investor recently bought a new position in Onconetix stock. Geode Capital Management LLC bought a new stake in Onconetix, Inc. (NASDAQ:ONCO) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 55,418 shares of the company’s stock, valued at approximately $35,000. Geode Capital Management LLC owned 0.67% of Onconetix at the end of the most recent reporting period. 23.89% of the stock is owned by institutional investors.

About Onconetix

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.